3 ms·
>Wojcicki was also building out an in-house drug-research group and tapping into a new revenue source: recruiting thousands of patients from 23andMe’s database
by rando444 7y ago
>Wojcicki was also building out an in-house drug-research group and tapping into a new revenue source: recruiting thousands of patients from 23andMe’s database for pharmaceutical firms’ clinical trials.
This is the most responsible way to use the data.
The way this model works is that a pharmaceutical companies have a question that requires a genetic database to answer. They then pay 23andMe for the results of these tests.
23andMe does not have to give up any customer data to any third party and can at the same time build a solid business model around using their data for positive medical advancements.